Nat Commun:器官移植新进展——免疫排斥反应可被克服

2015-07-22 sunshine 译 MedSci原创

据最新的一项小鼠体内器官移植研究表明,机体对移植器官排斥的“免疫记忆”作用可能不再是一个永久的状态了,这意味着后续的移植过程可以会成功。该研究结果在线发表于Nature Communications,该研究对小鼠进行了心脏移植,并诱导其产生免疫耐受,但是在首次移植一周后二次移植前发生了免疫排斥反应。研究过程中,第二次移植的心脏顺利的被机体所接受,而且在研究过程中保持着完整的功能。 在人类器官移植中


据最新的一项小鼠体内器官移植研究表明,机体对移植器官排斥的“免疫记忆”作用可能不再是一个永久的状态了,这意味着后续的移植过程可以会成功。该研究结果在线发表于Nature Communications,该研究对小鼠进行了心脏移植,并诱导其产生免疫耐受,但是在首次移植一周后二次移植前发生了免疫排斥反应。研究过程中,第二次移植的心脏顺利的被机体所接受,而且在研究过程中保持着完整的功能。

在人类器官移植中,有些移植受体可在数周内出现免疫排斥反应,而且由于免疫记忆--免疫系统的一种警戒状态--的存在,再次移植时甚至会更快地出现排斥反应。

“尽管移植耐受暂时可被克服,但是它会似乎是一种有弹性且持久的状态,”来自伊利诺斯州芝加哥大学移植手术学教授,本研究的共同资深作者Anita Chong说道,“我们的研究结果改变了人们对移植排斥反应的免疫记忆是永久的这一看法。”

对终末期器官衰竭的患者来说,必须终身使用免疫抑制药物以防止免疫排斥反应的发生。
可以在一些患者中诱导免疫耐受-机体接受异体器官移植而不产生长期的免疫抑制作用-的产生,但是这存在一定的难度。但即使是经过长期的耐受之后,这些患者仍会被一些因素,如细菌感染,引发器官免疫排斥反应。医生们认为这可能是因为免疫系统对排斥有记忆,并防止将来器官移植的免疫耐受。

细菌一旦被清除,免疫耐受立马恢复

关于小鼠的实验室研究工作中免疫耐受可以建立,但是2个月后细菌感染给免疫耐受带来了挑战。一半的小鼠发生了器官移植排斥反应。但是研究人员发现,一旦免疫系统清除了细菌,它便可自发的恢复到早前的免疫耐受状态,并可以接受另外的心脏移植手术。

该动物实验增加了应用到人类身上的希望。“尽管小鼠和人类获得移植耐受性的方法有差异,但是维持这种耐受的机制却是相似的。”来自芝加哥大学,该研究的共同资深作者,医学教授Marisa Alegre说道,“我们的研究结果表明,对经历过器官排斥的耐受患者可以使用短期的免疫抑制药物治疗,以保护移植的器官,然后在免疫耐受恢复之后立刻停止给药。

“我们目前的工作是更加详细的了解这种耐受恢复的机制是如何发生的。”来自芝加哥大学分子医学的研究生作者Michelle Miller说道,“我们想找出是否有其他可帮助调节耐受并预防排斥记忆的机制。”

作者们在文章中总结道“他们可以为不遵循同种致敏作用的移植结果提供实验证据”,并补充道,“调节免疫记忆可以控制感染引发的器官排斥记忆。”

原始出处:

Miller ML, Daniels MD, Wang T, Chen J, Young J, Xu J, Wang Y, Yin D, Vu V, Husain AN, Alegre ML, ChongAS. Spontaneous restoration of transplantation tolerance after acute rejection.Nat Commun. 2015 Jul 7;6:7566. doi: 10.1038/ncomms8566.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2086809, encodeId=236d208680926, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Apr 10 01:20:00 CST 2016, time=2016-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880742, encodeId=8a381880e4215, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 08 16:20:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262965, encodeId=f00112629654e, content=<a href='/topic/show?id=3c0f56643cd' target=_blank style='color:#2F92EE;'>#排斥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56643, encryptionId=3c0f56643cd, topicName=排斥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Fri Jul 24 07:20:00 CST 2015, time=2015-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532133, encodeId=732b1532133a7, content=<a href='/topic/show?id=54bb56644f5' target=_blank style='color:#2F92EE;'>#排斥反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56644, encryptionId=54bb56644f5, topicName=排斥反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=546412326777, createdName=smallant2006, createdTime=Fri Jul 24 07:20:00 CST 2015, time=2015-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1576970, encodeId=9f7615e697091, content=<a href='/topic/show?id=201f29042ff' target=_blank style='color:#2F92EE;'>#免疫排斥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29042, encryptionId=201f29042ff, topicName=免疫排斥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b216353032, createdName=ms6829001416292975, createdTime=Fri Jul 24 07:20:00 CST 2015, time=2015-07-24, status=1, ipAttribution=)]
    2016-04-10 liuli5079
  2. [GetPortalCommentsPageByObjectIdResponse(id=2086809, encodeId=236d208680926, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Apr 10 01:20:00 CST 2016, time=2016-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880742, encodeId=8a381880e4215, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 08 16:20:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262965, encodeId=f00112629654e, content=<a href='/topic/show?id=3c0f56643cd' target=_blank style='color:#2F92EE;'>#排斥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56643, encryptionId=3c0f56643cd, topicName=排斥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Fri Jul 24 07:20:00 CST 2015, time=2015-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532133, encodeId=732b1532133a7, content=<a href='/topic/show?id=54bb56644f5' target=_blank style='color:#2F92EE;'>#排斥反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56644, encryptionId=54bb56644f5, topicName=排斥反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=546412326777, createdName=smallant2006, createdTime=Fri Jul 24 07:20:00 CST 2015, time=2015-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1576970, encodeId=9f7615e697091, content=<a href='/topic/show?id=201f29042ff' target=_blank style='color:#2F92EE;'>#免疫排斥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29042, encryptionId=201f29042ff, topicName=免疫排斥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b216353032, createdName=ms6829001416292975, createdTime=Fri Jul 24 07:20:00 CST 2015, time=2015-07-24, status=1, ipAttribution=)]
    2016-01-08 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=2086809, encodeId=236d208680926, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Apr 10 01:20:00 CST 2016, time=2016-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880742, encodeId=8a381880e4215, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 08 16:20:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262965, encodeId=f00112629654e, content=<a href='/topic/show?id=3c0f56643cd' target=_blank style='color:#2F92EE;'>#排斥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56643, encryptionId=3c0f56643cd, topicName=排斥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Fri Jul 24 07:20:00 CST 2015, time=2015-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532133, encodeId=732b1532133a7, content=<a href='/topic/show?id=54bb56644f5' target=_blank style='color:#2F92EE;'>#排斥反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56644, encryptionId=54bb56644f5, topicName=排斥反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=546412326777, createdName=smallant2006, createdTime=Fri Jul 24 07:20:00 CST 2015, time=2015-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1576970, encodeId=9f7615e697091, content=<a href='/topic/show?id=201f29042ff' target=_blank style='color:#2F92EE;'>#免疫排斥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29042, encryptionId=201f29042ff, topicName=免疫排斥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b216353032, createdName=ms6829001416292975, createdTime=Fri Jul 24 07:20:00 CST 2015, time=2015-07-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2086809, encodeId=236d208680926, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Apr 10 01:20:00 CST 2016, time=2016-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880742, encodeId=8a381880e4215, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 08 16:20:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262965, encodeId=f00112629654e, content=<a href='/topic/show?id=3c0f56643cd' target=_blank style='color:#2F92EE;'>#排斥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56643, encryptionId=3c0f56643cd, topicName=排斥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Fri Jul 24 07:20:00 CST 2015, time=2015-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532133, encodeId=732b1532133a7, content=<a href='/topic/show?id=54bb56644f5' target=_blank style='color:#2F92EE;'>#排斥反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56644, encryptionId=54bb56644f5, topicName=排斥反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=546412326777, createdName=smallant2006, createdTime=Fri Jul 24 07:20:00 CST 2015, time=2015-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1576970, encodeId=9f7615e697091, content=<a href='/topic/show?id=201f29042ff' target=_blank style='color:#2F92EE;'>#免疫排斥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29042, encryptionId=201f29042ff, topicName=免疫排斥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b216353032, createdName=ms6829001416292975, createdTime=Fri Jul 24 07:20:00 CST 2015, time=2015-07-24, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2086809, encodeId=236d208680926, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Apr 10 01:20:00 CST 2016, time=2016-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880742, encodeId=8a381880e4215, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 08 16:20:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262965, encodeId=f00112629654e, content=<a href='/topic/show?id=3c0f56643cd' target=_blank style='color:#2F92EE;'>#排斥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56643, encryptionId=3c0f56643cd, topicName=排斥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Fri Jul 24 07:20:00 CST 2015, time=2015-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532133, encodeId=732b1532133a7, content=<a href='/topic/show?id=54bb56644f5' target=_blank style='color:#2F92EE;'>#排斥反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56644, encryptionId=54bb56644f5, topicName=排斥反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=546412326777, createdName=smallant2006, createdTime=Fri Jul 24 07:20:00 CST 2015, time=2015-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1576970, encodeId=9f7615e697091, content=<a href='/topic/show?id=201f29042ff' target=_blank style='color:#2F92EE;'>#免疫排斥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29042, encryptionId=201f29042ff, topicName=免疫排斥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b216353032, createdName=ms6829001416292975, createdTime=Fri Jul 24 07:20:00 CST 2015, time=2015-07-24, status=1, ipAttribution=)]

相关资讯

三类器官移植医院资质将被吊销

有资质医院面临重新洗牌 预计需新增100家移植医院 “下一步要对全国169家拥有器官移植资质的医院重新洗牌,明确准入机制,同时取消部分移植医院的资格。”中国人体器官捐献与移植委员会主任委员黄洁夫在日前举办的2014器官捐献国际合作论坛上表示。 即将出局的医院包括三类,一是没有开展人体器官移植服务的;二是器官移植治疗效果不好,1年成活率、5年成活率远远低于其他医院的;三是违规做器官移植手术,包

Nat Commu:器官移植排斥反应可能不是永久性!

近日,来自美国芝加哥大学的研究人员在国际学术期刊Nature Communication在线发表了一项最新研究进展,他们发现器官移植过程中免疫耐受的存在并非永久性,在已经形成免疫耐受的病人体内还可能再发生免疫排斥,但不会形成永久性的免疫记忆,而调节性T细胞在免疫耐受形成过程中发挥重要作用。器官移植是治疗器官衰竭的一种重要方法,进行了器官移植的病人往往需要终身服用免疫抑制药物,也有一些病人可以经过一

Br J Surg:抗凝剂,器官移植新尝试

在器官移植过程中,器官会有较大的损坏,但发表在BJS (British Journal of Surgery)杂志上的一篇新文章提出了一种最佳的保护策略,最大程度保证移植器官的安全,让它们在手术后尽快发挥正常功能。当器官从供体向受体移植,有一段时间器官中是没有正常血流的,缺血本身即可引起组织损伤。血液恢复供应(再灌注)中,也会对器官造成额外损伤。研究人员Thierry Hauet博士表示:不知道抗

生命速递—302医院实施首例多器官捐献移植术

12月14日上午,解放军第302医院手术室内无影灯闪烁,各种手术用具准备完毕,医护人员忙碌的身影来回穿梭……一场生命接力即将拉开序幕。 手术实施之前,全体医护人员在中国红十字总会中国人体器官捐献管理中心工作人员的带领下,向自愿捐献器官的脑死亡患者王某(化名)默哀一分钟,对他高尚的人道主义精神致敬。同一时间,静静等待在隔壁手术室的肝脏肿瘤患者李某(化名)和北京大学第三医院手术室内多囊肾患者兄妹也在

奥巴马解除艾滋病感染者器官移植研究禁令

美国总统奥巴马11月21日签署一项名为《艾滋病病毒器官政策公平法》的法案,解除了对艾滋病病毒感染者间器官移植的研究禁令,向允许实施这类器官移植迈出一大步。 《艾滋病病毒器官政策公平法》的英文首字母简写为HOPE,因此也被称为《希望法》。此前,美国众议院与参议院已分别批准了《希望法》法案。 奥巴马当天在一份声明中说,几十年来,艾滋病病毒感染者间器官移植在美国属非法,甚至研究进行这样的

Brincidofovi有望成为器官移植患者的抗病毒**药物

一般而言,腺病毒不会对人体健康造成大的威胁,因为人体免疫系统就可以应对它所引起的呼吸或消化系统感染,但对于骨髓移植或其他器官移植的病人,腺病毒感染往往是致命的,死亡率高达80%。 市场上尚且没有经FDA批准的腺病毒治疗药物。临床医生往往会选择静脉注射产品Cidofovir(西多福韦),该药物本来是用来治疗AIDS患者发生的眼部巨细胞病毒感染。但Cidofovir副作用明显——肾功能损害。